ORGS vs. TLPH, AVTX, VINC, NERV, NRSN, VBIV, NRBO, INDP, COCP, and HUGE
Should you be buying Orgenesis stock or one of its competitors? The main competitors of Orgenesis include Talphera (TLPH), Avalo Therapeutics (AVTX), Vincerx Pharma (VINC), Minerva Neurosciences (NERV), NeuroSense Therapeutics (NRSN), VBI Vaccines (VBIV), NeuroBo Pharmaceuticals (NRBO), Indaptus Therapeutics (INDP), Cocrystal Pharma (COCP), and FSD Pharma (HUGE). These companies are all part of the "pharmaceutical preparations" industry.
Orgenesis (NASDAQ:ORGS) and Talphera (NASDAQ:TLPH) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their media sentiment, institutional ownership, community ranking, valuation, earnings, risk, dividends, profitability and analyst recommendations.
Talphera has a net margin of 0.00% compared to Orgenesis' net margin of -1,010.50%. Talphera's return on equity of -71.67% beat Orgenesis' return on equity.
Talphera has higher revenue and earnings than Orgenesis. Talphera is trading at a lower price-to-earnings ratio than Orgenesis, indicating that it is currently the more affordable of the two stocks.
Talphera has a consensus price target of $6.00, indicating a potential upside of 488.24%. Given Talphera's higher possible upside, analysts plainly believe Talphera is more favorable than Orgenesis.
Talphera received 1 more outperform votes than Orgenesis when rated by MarketBeat users.
22.6% of Orgenesis shares are owned by institutional investors. Comparatively, 37.7% of Talphera shares are owned by institutional investors. 7.1% of Orgenesis shares are owned by company insiders. Comparatively, 3.0% of Talphera shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
In the previous week, Talphera had 1 more articles in the media than Orgenesis. MarketBeat recorded 1 mentions for Talphera and 0 mentions for Orgenesis. Orgenesis' average media sentiment score of 0.00 equaled Talphera'saverage media sentiment score.
Orgenesis has a beta of 1.2, indicating that its stock price is 20% more volatile than the S&P 500. Comparatively, Talphera has a beta of 0.46, indicating that its stock price is 54% less volatile than the S&P 500.
Summary
Talphera beats Orgenesis on 10 of the 15 factors compared between the two stocks.
Get Orgenesis News Delivered to You Automatically
Sign up to receive the latest news and ratings for ORGS and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ORGS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Orgenesis Competitors List
Related Companies and Tools
